A4 Study (NCT02008357) preclinical solanezumab arm halted 2020 after EXPEDITION3 + multi-cohort futility analysis; preclinical AD as solanezumab indication ruled out alongside mild-AD.

Evidence span

A4 Study (NCT02008357) preclinical solanezumab arm halted 2020 after EXPEDITION3 + multi-cohort futility analysis; preclinical AD as solanezumab indication ruled out alongside mild-AD.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

ACTC/Lilly A4 Study (NCT02008357), preclinical AD with PET-confirmed amyloid, halted March 2020.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required